Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.35 |
| ▸ | BRD4 | O60885 | 13/20 | 0.35 |
| ▸ | BRD2 | P25440 | 10/20 | 0.35 |
| ▸ | BRD3 | Q15059 | 10/20 | 0.35 |
| ▸ | CREBBP | Q92793 | 6/20 | 0.35 |
| ▸ | GAA | P10253 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | NMT1 | P30419 | 2/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15975168 | 0.80 | BRD4 (0.40) | BRD4BRD2BRD3CREBBPGAA | |
| SCHEMBL2116301 | 0.77 | MEN1 (0.44) | BRD4BRD2BRD3CREBBPGAA | |
| SCHEMBL174142 | 0.77 | BRD4 (0.35) | HDAC8BRD4GAAKDM4EALDH1A1 | |
| SCHEMBL2118787 | 0.76 | BRD4 (0.50) | BRD4BRD2CREBBPHTT | |
| SCHEMBL106685 | 0.74 | AURKA (0.49) | HDAC8BRD4HTTTP53 | |
| SCHEMBL16651268 | 0.74 | BRD4 (0.39) | HDAC8BRD4HTT | |
| SCHEMBL16339860 | 0.74 | HTT (0.33) | HDAC8BRD4HTT | |
| SCHEMBL16478319 | 0.74 | MAP2K1 (0.41) | BRD4CREBBPHTT | |
| SCHEMBL13078611 | 0.74 | HTT (0.33) | HDAC8BRD4HTT | |
| SCHEMBL20778075 | 0.74 | HTT (0.33) | NMT1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4720040-A1 | SULFONAMIDE COMPOUNDS BENEFICIAL IN NEUROPROTECTIVE TREATMENT | Lario Therapeutics Limited (GB) | 2026-04-08 | — | — | EP | disclosed |
| EP-4134364-B1 | BROMODOMAIN INHIBITORS | CELGENE QUANTICEL RES INC (US) | 2025-07-30 | — | — | EP | disclosed |
| US-20240425481-A1 | SUBSTITUTED BENZIMIDAZOLES, THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS | EPIGENETIX, INC. | 2024-12-26 | — | — | US | disclosed |
| WO-2024246522-A1 | SULFONAMIDE COMPOUNDS BENEFICIAL IN NEUROPROTECTIVE TREATMENT | LARIO THERAPEUTICS LIMITED (GB) | 2024-12-05 | — | — | WO | disclosed |
| US-20240182490-A1 | BROMODOMAIN INHIBITORS | CELGENE QUANTICEL RESEARCH, INC. (US) | 2024-06-06 | — | — | US | disclosed |
| CN-118055926-A | ROCK2 inhibitors and uses thereof | 哈佛大学的校长及成员们 | 2024-05-17 | — | — | CN | disclosed |
| US-11884680-B2 | Bromodomain inhibitors | CELGENE QUANTICEL RESEARCH, INC. (US) | 2024-01-30 | — | — | US | disclosed |
| CN-110997656-B | Substituted indole compounds useful as TLR7/8/9 inhibitors | 百时美施贵宝公司 | 2023-04-14 | — | — | CN | disclosed |
| EP-4134364-A2 | BROMODOMAIN INHIBITORS | Celgene Quanticel Research, Inc. (US) | 2023-02-15 | — | — | EP | disclosed |
| WO-2023009475-A1 | ROCK2 INHIBITORS AND USES THEREOF | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2023-02-02 | — | — | WO | disclosed |
| EP-2858982-A1 | PYRIDINONE AND PYRIDAZINONE DERIVATIVES | AbbVie Inc. (US) | 2015-04-15 | — | — | EP | disclosed |
| EP-2858990-A1 | PYRIDINONE AND PYRIDAZINONE DERIVATIVES | AbbVie Inc. (US) | 2015-04-15 | — | — | EP | disclosed |
| WO-2013188381-A1 | PYRIDINONE AND PYRIDAZINONE DERIVATIVES | ABBVIE INC. (US) | 2013-12-19 | — | — | WO | disclosed |
| WO-2013185284-A1 | PYRIDINONE AND PYRIDAZINONE DERIVATIVES | ABBOTT LABORATORIES (US) | 2013-12-19 | — | — | WO | disclosed |
| US-8158652-B2 | 1-Difluoromethyl-5-{4-[3-(1-piperidinyl)propoxy]phenyl}-2(1H)-pyridone; compounds act as histamine-H3 receptor antagonistic substances or inverse-agonistic substances; useful as preventives or remedies for various circular system diseases, nervous system diseases, metabolic system diseases | MSD K.K. (JP) | 2012-04-17 | — | — | US | disclosed |
| EP-2323978-A1 | AMIDE COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2011-05-25 | — | — | EP | disclosed |
| WO-2010018874-A1 | AMIDE COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-02-18 | — | — | WO | disclosed |
| US-20100041891-A1 | AMIDE COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-02-18 | — | — | US | disclosed |
| US-20080269287-A1 | Substituted Pyridone Derivative | MSD K.K. (JP) | 2008-10-30 | — | — | US | disclosed |
| EP-1820797-A1 | SUBSTITUTED PYRIDONE DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2007-08-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100041891-A1 | AMIDE COMPOUND | GPR52, GPR132, NR5A2 | HDAC8 573/4885BRD4 250/4885BRD2 600/4885 |
| US-20240182490-A1 | BROMODOMAIN INHIBITORS | BRD3, EP300, BRPF3 | HDAC8 29/4885BRD4 5/4885BRD2 8/4885 |
| US-20080269287-A1 | Substituted Pyridone Derivative | HRH3, HRH4, HRH1 | HDAC8 1915/4885BRD4 492/4885BRD2 984/4885 |
| US-20240425481-A1 | SUBSTITUTED BENZIMIDAZOLES, THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS | BRD3, BRDT, BRD4 | HDAC8 30/4885BRD4 3/4885BRD2 6/4885 |
| US-11884680-B2 | Bromodomain inhibitors | BRD3, EP300, BRPF3 | HDAC8 29/4885BRD4 5/4885BRD2 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.